Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).

Trial Details

NCT ID

NCT06374459

Phase

PHASE1 / PHASE2

Sponsor

Washington University School of Medicine

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

Zumsemetinib
Capecitabine
Zoledronic acid
Denosumab

Locations (sample)

Westwood, Kansas, United States|39.04056,-94.6169
Rochester, Minnesota, United States|44.02163,-92.4699
St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

Hormone receptor-positive, HER2-negative metastatic breast cancer.
Measurable or non-measurable but evaluable disease by RECIST v1.1.
Candidate for capecitabine treatment per physician decision. See below phase-specific eligibility criteria for further guidance.
No more than one prior chemotherapy for metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →